Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of malignant melanoma~* Previously-treated or untreated unresectable Stage III or Stage IV melanoma~* Measurable/evaluable disease per modified World Health Organization (mWHO) criteria, within 28 days of first dose of study drug~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Active brain metastases~* Primary ocular or mucosal melanoma~* History of or current active autoimmune disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Ipilimumab (Type: EXPERIMENTAL): Ipilimumab Intravenous Injection 3 mg/kg for every 3 weeks upto 4 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).